Evidence map›Paper›PMID 21779086›Full record

Trial reportObesity (Silver Spring, Md.)2011

Four-year weight losses in the Look AHEAD study: factors associated with long-term success.

Thomas A Wadden, Rebecca H Neiberg, Rena R Wing, Jeanne M Clark, Linda M Delahanty, James O Hill, Jonathan Krakoff, Amy Otto, Donna H Ryan, Mara Z Vitolins and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04614545 (The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits), which is not on this map. Cited by 240 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04614545 phase4completednot on this mapstarted 2021, after this paper: background citation

The Use of a Virtual Weight Management Program for Prescription of Phentermine in Patients With Overweight or Obesity Compared to Standard Face to Face Visits

TypeinterventionalSponsorThe Cleveland ClinicRan2021 to 2022Enrolled70ConditionsObesityArmsPhentermine 37.5 Mg, Dietary program, Exercise program
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Determinants of weight loss maintenance: a systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2019
    Pooled it
  5. Pooled it
  6. Pooled it
  7. A systematic review of motivational interviewing for weight loss among adults in primary care.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2015
    Pooled it
  8. Pooled it
  9. Effectiveness of weight loss interventions--is there a difference between men and women: a systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2015
    Pooled it
  10. Guideline
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas A WaddenDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. Wadden@mail.med.upenn.edu
Rebecca H Neiberg
Rena R Wing
Jeanne M Clark
Linda M Delahanty
James O Hill
Jonathan Krakoff
Amy Otto
Donna H Ryan
Mara Z Vitolins
Look AHEAD Research Group

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Julie Mathieu · 1986 to 2026
$41.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HOGE, ELIZABETH A · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BRYAN C BERGMAN · 1995 to 2026
$32.6M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PLISZKA, STEVEN R. · 1985 to 2008
$23.1M
SHOW PROJECTU01DK057154 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1999 to 2020
$23.1M
Look AHEAD: Action for Health DiabetesU01DK057178 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1999 to 2020
$21.2M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
The Look AHEAD Continuation: Action for Health in DiabetesU01DK057078 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, KAREN C · 1999 to 2020
$20.1M
Intramural NIH HHSNCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01RR000056NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01RR0021140NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR01066NCRR NIH HHS M01RR01346NCRR NIH HHS M01RR02719NCRR NIH HHS UL1 RR 024153NCRR NIH HHS UL1 RR024153NIDDK NIH HHS DK 046204NIDDK NIH HHS DK56990NIDDK NIH HHS DK56992NIDDK NIH HHS DK57002NIDDK NIH HHS DK57008NIDDK NIH HHS DK57078NIDDK NIH HHS DK57131NIDDK NIH HHS DK57135NIDDK NIH HHS DK57136NIDDK NIH HHS DK57149NIDDK NIH HHS DK57151NIDDK NIH HHS DK57154NIDDK NIH HHS DK57171NIDDK NIH HHS DK57177NIDDK NIH HHS DK57178NIDDK NIH HHS DK57182NIDDK NIH HHS DK57219NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK48520NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219
6 · The paper itself

Abstract

This report provides a further analysis of the year 4 weight losses in the Look AHEAD (Action for Health in Diabetes) study and identifies factors associated with long-term success. A total of 5,145 overweight/obese men and women with type 2 diabetes were randomly assigned to an intensive lifestyle intervention (ILI) or a usual care group, referred to as Diabetes Support and Education (DSE). ILI participants were provided approximately weekly group or individual treatment in year 1; continued but less frequent contact was provided in years 2-4. DSE participants received three group educational sessions in all years. As reported previously, at year 4, ILI participants lost an average of 4.7% of initial weight, compared with 1.1% for DSE (P < 0.0001). More ILI than DSE participants lost ≥ 5% (46% vs. 25%, P < 0.0001) and ≥ 10% (23% vs. 10%, P < 0.0001) of initial weight. Within the ILI, achievement of both the 5% and 10% categorical weight losses at year 4 was strongly related to meeting these goals at year 1. A total of 887 participants in ILI lost ≥ 10% at year 1, of whom 374 (42.2%) achieved this loss at year 4. Participants who maintained the loss, compared with those who did not, attended more treatment sessions and reported more favorable physical activity and food intake at year 4. These results provide critical evidence that a comprehensive lifestyle intervention can induce clinically significant weight loss (i.e., ≥ 5%) in overweight/obese participants with type 2 diabetes and maintain this loss in more than 45% of patients at 4 years.

Indexed as

DietExerciseHealth EducationWeight LossWeight Reduction ProgramsDiabetes Mellitus, Type 2Energy IntakeFemaleGroup ProcessesHumansLife StyleMaleMiddle AgedObesityTreatment Outcome

Identifiers

PMID21779086
PMCPMC3183129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.